TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36260786
Drug: Serial ctDNA
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial ctDNA surveillance with delayed adjuvant therapy (Arm 2)
Study: 34588245
Drug: eMMa (electronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: eMMa (electronic medication management support system)
Study: 36038003
Drug: Tanezumab 10
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 10 mg subcutaneously
Study: 33190355
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake at breakfast (10 g increase)
Study: 33190355
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake at lunch (10 g increase)
Study: 32938772
Drug: All patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients post-discontinuation (≤30 days)
Study: 35410753
Drug: SID142 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SID142 (200 mg cilostazol and 160 mg Ginkgo biloba leaf extract, once daily)
Study: 35410753
Drug: Renexin (cilostazol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renexin (cilostazol and Ginkgo biloba leaf extract, twice daily)
Study: 33794293
Drug: TP53 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TP53 gene alteration pre-treatment and at C2D1
Study: 33794293
Drug: RB1 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RB1 gene alteration pre-treatment and at C2D1
Study: 33794293
Drug: PTEN gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTEN gene alteration pre-treatment and at C2D1
Study: 33794293
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who were positive pre-treatment and converted to undetectable
Study: 35557278
Drug: BAPN (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAPN (300 mg/kg/day in water)
Study: 32760097
Drug: Regular-exercise group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular-exercise group (conventional physical therapy and scapular muscle strengthening exercises)
Study: 36109008
Drug: Sodium Citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Citrate (SC, 500 mg/kg body mass)
Study: 36109008
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Bicarbonate (SB, 300 mg/kg body mass)
Study: 32827501
Drug: Intranasal AVP
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal AVP (20 IU)
Study: 36131289
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive therapy (iCBT) involving 7 weekly online modules delivered via a perinatal mental healthcare app
Study: 36131289
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive therapy (iCBT)
Study: 32810383
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg teneligliptin
Study: 35960044
Drug: Lidocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1 mg/kg intravenously during anesthesia induction, then continuously pumped at 1 mg/kg/h until operation)
Study: 32039635
Drug: Brief Behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Behavioral Therapy for Insomnia (BBTi)
Study: 35508338
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 20 mg/kg daily
Study: 32038026
Drug: Six-month dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-month dual antiplatelet therapy (DAPT) after BP-SES implantation
Study: 32038026
Drug: Twelve-month dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twelve-month dual antiplatelet therapy (DAPT) after BP-SES implantation
Study: 32522198
Drug: Early intravenous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intravenous metoprolol
Study: 34431174
Drug: Intervention twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention twice per week (20-30 min sessions for 10 weeks, 1000 trials; 400-600 min total)
Study: 33628717
Drug: Propolis (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis (75 mg three times a day)
Study: 35386013
Drug: FMXIN001 (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMXIN001 (intranasal powder-based naloxone formulation)
Study: 35386013
Drug: Narcan® (nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narcan® (nasal liquid spray)
Study: 32472417
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for MBC patients with low RS
Study: 32472417
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for FBC patients with low RS
Study: 32472417
Drug: Overall chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall chemotherapy rates
Study: 86266805
Drug: Z5: streptomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z5: streptomycin plus isoniazid plus pyrazinamide twice weekly for 2 months without rifampin
Study: 34051342
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BRJ) - 70 ml dose per day for 20 days (12.5 mmol nitrate per day; n = 11)
Study: 36461695
Drug: Pre-urodynamic single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-urodynamic single-dose Levofloxacin (500 mg administered one hour before the urodynamic study)
Study: 36461695
Drug: Post-urodynamic Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-urodynamic Levofloxacin (500 mg once daily for three days following the urodynamic study)
Study: 33599247
Drug: Ivermectin 6
Normalized name: ivermectin 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 6 mg regime
Study: 33599247
Drug: Ivermectin 12
Normalized name: Ivermectin 12 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 12 mg regime (given Q84 h for 2 weeks)
Study: 33599247
Drug: Ivermectin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (both doses)
Study: 36173481
Drug: High Na+
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Na+ (60 mmol L-1 sodium)
Study: 36173481
Drug: Low Na+
Normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Na+ (21 mmol L-1 sodium)
Study: 32398852
Drug: Simultaneous double-protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous double-protocol therapy (intravitreal dexamethasone implant and ranibizumab)
Study: 32512517
Drug: HIV-1 RNA
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 RNA ≥5 log10 copies/ml
Study: 35768119
Drug: Preoperative carbohydrate-loading
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative carbohydrate-loading drinks (4×200 mL evening before surgery and 2×200 mL the morning of surgery) and early postoperative nutritional protein supplement drinks two times per day for 14 days
Study: 32584754
Drug: Advertisement cue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advertisement cue combination (financial security and taking control of one's future)
Study: 33086160
Drug: Mixed amphetamine
Normalized name: mixed amphetamine salts 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amphetamine salts-extended-release (MAS-ER), titrated up to 80 mg daily
Study: 35247334
Drug: Topical LHA510
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical LHA510 administered twice a day for 8 weeks and then 3 times a day for the last 4 weeks
Study: 35247334
Drug: Vehicle (placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (placebo) administered twice a day for 8 weeks and then 3 times a day for the last 4 weeks
Study: 35247334
Drug: Topical LHA510
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical LHA510
Study: 32164673
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy (trimethoprim 160 mg/sulfamethoxazole 800 mg twice a day plus folic acid 5 mg daily or doxycycline 100 mg once daily if body weight is < 50 kg or 100 mg twice daily if ≥50 kg)
Study: 34982157
Drug: Weekly midturbinate
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly midturbinate swabbing
Study: 34698931
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g TXA i.v. preoperatively
Study: 34133089
Drug: Vortioxetine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (5 mg)
Study: 34133089
Drug: Vortioxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (10 mg)
Study: 34133089
Drug: Vortioxetine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (15 mg)
Study: 34133089
Drug: Vortioxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (20 mg)
Study: 32936480
Drug: Tisseel plus
Normalized name: Tisseel
DrugBank: Human thrombin (DB11571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisseel plus PEP (TEPEP) patch
Study: 32936480
Drug: Tisseel patch
Normalized name: Tisseel
DrugBank: Human thrombin (DB11571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisseel patch alone
Study: 36045119
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral hydrocortisone
Study: 35150597
Drug: Bismuth-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy (BQT)
Study: 35150597
Drug: Rabeprazole plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole plus amoxicillin dual therapy (RADT)
Study: 33283636
Drug: Management of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management of local intravascular coagulopathy (LIC) with low‐molecular‐weight heparin (LMWH) and other anticoagulants
Study: 33283636
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment options including compression, sclerotherapy, laser therapy, cryoablation, and surgery
Study: 33283636
Drug: Targeted molecular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Targeted molecular therapies acting on the PI3Kinase/AKT/mTOR pathway
Study: 34336630
Drug: 0.5 µ/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 µ/kg dexmedetomidine with 20 mL bupivacaine 0.125% (Group L)
Study: 34336630
Drug: 1 µ/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µ/kg dexmedetomidine with 20 mL bupivacaine 0.125% (Group M)
Study: 34336630
Drug: 1.5 µ/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 µ/kg dexmedetomidine with 20 mL bupivacaine 0.125% (Group H)
Study: 33715871
Drug: Ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal acetate (UPA) 10 mg orally once a day for 12 weeks
Study: 33715871
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin acetate (LEU) 1.88 mg or 3.75 mg subcutaneously at weeks 0, 4, and 8
Study: 35477635
Drug: REL-1017 25
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: REL-1017 25 mg (75 mg loading dose on day 1)
Study: 35477635
Drug: REL-1017 50
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: REL-1017 50 mg (100 mg loading dose on day 1)
Study: 36438822
Drug: Kampo group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kampo group receiving mixed extract granules of kakkonto (2.5 g) and shosaikotokakikyosekko (2.5 g) three times a day for 14 days in addition to conventional treatment
Study: 36438822
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving conventional treatment for symptom relief such as antipyretics and antitussives
Study: 34127045
Drug: Ca-polyP in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca-polyP in combination with biphasic calcium phosphate (BCP)
Study: 34850164
Drug: eGo-style ENDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGo-style ENDS with 36 mg/ml nicotine liquid
Study: 34850164
Drug: eGo-style ENDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGo-style ENDS with 0 mg/ml nicotine liquid
Study: 34850164
Drug: eGo-style ENDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGo-style ENDS with 8 mg/ml nicotine liquid
Study: 34969263
Drug: Metal Telescopic
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metal Telescopic Dilator (MTD) using sequential MTD (9-30F)
Study: 35470551
Drug: Amphetamine (AMPH)
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine (AMPH) 30 mg
Study: 39463173
Drug: Desvenlafaxine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (50 mg/day)
Study: 35937386
Drug: Microneedle injection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedle injection of MEBO combined with blood transfusion
Study: 35937386
Drug: Moist exposed
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moist exposed burn ointment (MEBO) combined with blood transfusion
Study: 35937386
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment external application
Study: 34167872
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus standard of care
Study: 32788001
Drug: Irradiated teeth
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiated teeth (exposed to radiation at a dose fraction of two Gy for five consecutive days until reaching a total dose of 60 Gy)
Study: 33792451
Drug: Noninvasive ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive ventilation (NIV) prescribed to patients with SVC decline; reasons for prescription.
Study: 35605013
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg daily oral tamoxifen
Study: 35605013
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg daily oral tamoxifen
Study: 35343332
Drug: Contrast with
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast with compression (CwC) therapy
Study: 32914483
Drug: Black barberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black barberry extract (1,000 mg, two capsules daily for 12 weeks)
Study: 32914483
Drug: Maltodextrin placebo
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin placebo (two capsules daily for 12 weeks)
Study: 35895150
Drug: Khanya intervention
Normalized name: Khaya senegalensis bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Khanya intervention (cognitive-behavioral therapy-based)
Study: 36302965
Drug: Oxytocin nasal
Normalized name: oxytocin Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin nasal spray (16 IU, administered morning and night for 12 weeks)
Study: 36302965
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray (administered morning and night for 12 weeks)
Study: 32052341
Drug: Aflibercept with
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept with chemotherapy
Study: 36121843
Drug: Fibersol-2 low
Normalized name: Dianeal Low Calcium 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibersol-2 low dose (2.5g)
Study: 36121843
Drug: Fibersol-2 high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibersol-2 high dose (5g)
Study: 38909229
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic gel
Study: 36336989
Drug: Hydroxypropyl chitosan-based
Normalized name: hydroxypropyl chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxypropyl chitosan-based 80 mg/g ciclopirox nail lacquer
Study: 35946753
Drug: Placebo protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo protocol (250 mL of water)
Study: 33629490
Drug: Haemoglobin levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemoglobin levels of 70–89 g/l at 6+0–13+6 weeks
Study: 33629490
Drug: Haemoglobin levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemoglobin levels of 110–129 g/l at 6+0–13+6 weeks
Study: 35168560
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by 6 months of oral uracil and tegafur plus leucovorin (UFT/LV)
Study: 33922546
Drug: Sodium glucose
Normalized name: Sodium glucose cotransporter subtype 2 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium glucose cotransporter 2 inhibitors (SGLT2i)
Study: 35715681
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Macrogol-based solution the day prior to examination (Regimen A)
Study: 35715681
Drug: Fractionated dose
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated dose of Macrogol-based solution 2 days before examination (Regimen B)
Study: 35715681
Drug: Fractionated dose
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated dose of Macrogol-based solution 3 days before examination (Regimen C)
Study: 37668277
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo infusion
Study: 39075484
Drug: Aspirin cessation
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin cessation
Study: 33170486
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) treatment
Study: 34960061
Drug: LC-Plasma tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC-Plasma tablets (approximately 100 billion cells/day) for 8 weeks
Study: 32316993
Drug: Onsite molecular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Onsite molecular testing using GeneXpert Edge, process redesign to facilitate same-day TB diagnosis and treatment, and performance feedback
Study: 34995992
Drug: Escitalopram monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram monotherapy for 8-12 weeks
Study: 35212574
Drug: Cytoreductive nephrectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive nephrectomy (CN) with systemic therapy
Study: 34107013
Drug: Upadacitinib 45
Normalized name: upadacitinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 45 mg once daily (QD)
Study: 33021715
Drug: Antihypertensive drug
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drug and lifestyle intervention therapies
Study: 33021715
Drug: Standard antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antihypertensive drug intervention therapy
Study: 32063109
Drug: N-acetylcysteine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (two 600 mg tablets)
Study: 33632752
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive ablative therapy to prostate±pelvic lymph node dissection (PLND)
Study: 33632752
Drug: All arms
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All arms will receive standard systemic therapy with ADT±upfront systemic chemotherapy or androgen receptor agents.
Study: 33526484
Drug: Oxfendazole (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxfendazole (0.5 to 60 mg/kg)
Study: 33486643
Drug: Risk prediction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk prediction score based on 7 factors (stoma creation, Peritoneal Cancer Index score ≥15, hyponatremia, in-hospital major complication, preoperative chemotherapy, anemia, discharge to nursing home)
Study: 32152693
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion with indwelling needles
Study: 32152693
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion with steel needles
Study: 35337021
Drug: Baseline viral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline viral load <2 mill IU/mL
Study: 36243227
Drug: Direct consultations
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct consultations with a medical physicist during treatment simulation and before the first treatment.
Study: 32324840
Drug: Individualized homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized homeopathic treatment (IHT) with homeopathic remedies at 30C (10-60) and 200C (10-400) dilutions
Study: 33662894
Drug: Cenobamate 100
Normalized name: cenobamate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate 100 mg once daily
Study: 33662894
Drug: Cenobamate 200
Normalized name: cenobamate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate 200 mg once daily
Study: 33662894
Drug: Cenobamate 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate 400 mg once daily